Phase 3 trial of 344 participants with muscle-invasive bladder cancer ineligible for or declining cisplatin: perioperative enfortumab vedotin-pembrolizumab plus surgery vs surgery alone improved 2-year EFS (74.7% vs 39.4%; HR 0.40) and OS (HR 0.50); grade ≥3 AEs 71.3% vs 45.9%.
RCTn = 344
Vulsteke et al. Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer